Kistler-Tiffany Companies’s Sage Therapeutics SAGE Stock Holding History

Kistler-Tiffany Companies’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$4.7K	Hold	100	–	–	﹤0.01%	765
2023 Q1	$4.2K	Hold	100	–	–	﹤0.01%	697
2022 Q4	$3.81K	Hold	100	–	–	﹤0.01%	703
2022 Q3	$4K	Hold	100	–	–	﹤0.01%	693
2022 Q2	$3K	Hold	100	–	–	﹤0.01%	698
2022 Q1	$3K	Hold	100	–	–	﹤0.01%	690
2021 Q4	$4K	Hold	100	–	–	﹤0.01%	662
2021 Q3	$4K	Hold	100	–	–	﹤0.01%	649
2021 Q2	$6K	Hold	100	–	–	﹤0.01%	615
2021 Q1	$7K	Hold	100	–	–	﹤0.01%	557
2020 Q4	$9K	Hold	100	–	–	﹤0.01%	511
2020 Q3	$6K	Hold	100	–	–	﹤0.01%	530
2020 Q2	$4K	Hold	100	–	–	﹤0.01%	533
2020 Q1	$7K	Hold	100	–	–	﹤0.01%	476
2019 Q4	$7K	Hold	100	–	–	﹤0.01%	483
2019 Q3	$14K	Hold	100	–	–	0.01%	416
2019 Q2	$18K	Hold	100	–	–	0.01%	371
2019 Q1	$16K	Hold	100	–	–	0.01%	376
2018 Q4	$10K	Buy	+100	New	+$11.4K	﹤0.01%	406
2015 Q1	–	Sell	-4	Closed	–	–	611
2014 Q4	$0	Hold	4	–	–	﹤0.01%	619
2014 Q3	$0	Buy	+4	New	+$116	﹤0.01%	676

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kistler-Tiffany Companies's SAGE Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Sage Therapeutics (SAGE) position steady in Q2 2023 at 100 shares worth $4.7K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Kistler-Tiffany Companies first reported a position in SAGE in Q3 2014 and has held it in 21 quarters since. The position peaked at $18K in Q2 2019. 225 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

Kistler-Tiffany Companies held 100 shares of Sage Therapeutics worth $4.7K as of Q2 2023.
Kistler-Tiffany Companies left its Sage Therapeutics share count unchanged in Q2 2023.
Sage Therapeutics made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #765 holding.
Kistler-Tiffany Companies first reported a position in Sage Therapeutics in Q3 2014 and has held it in 21 quarters since.
Kistler-Tiffany Companies's Sage Therapeutics position peaked at $18K in Q2 2019.
225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.